Let's collaborate and create quality liposome encapsulated drugs together. Contact Us!
Discovery of mRNA and its function
In vitro translation of isolated mRNA in a cell-free system
Development of liposome–mRNA formulations
Development of cationic LNP–mRNA formulations
Free mRNA translation post intramuscular injection in mice
Injection of vasopressin mRNA into rat brain as protein replacement therapy for diabetes insipidus
Development of liposome–mRNA formulations as influenza vaccine
Injection of carcinoembryonic antigen mRNA into mouse muscle as a cancer vaccine
First clinical trial of mRNA-engineered dendritic cells (NCT00004211)
Nucleoside-modified mRNA shows reduced immunogenicity
Clinical trial of mRNA therapeutics using protamine–mRNA formulations (NCT00204607)
Clinical trial of LNP–mRNA formulations for cancer immunotherapies (NCT02316457)
SyVento BioTech is founded with a commitment to develop lipid-based drug delivery systems. Leveraging their experience and expertise, the company focuses on creating innovative and effective lipid nanoparticle solutions for RNA-based medicine
• Clinical trial of LNP–mRNA formulations as influenza vaccines (NCT03076385)
• Clinical trial of LNP–mRNA formulationsfor protein replacement therapies (NCT03375047)
• First in-human test of personalized mRNA cancer vaccines
• mRNA-1273 and BNT162b (LNP–mRNA
formulations) COVID-19 mRNA
vaccines obtained authorization from
regulatory agencies in multiple
countries
• Clinical trial of LNP formulations
delivering gene-editing components
for genetic disorders (NCT04601051)
SyVento and OncoArendi (currently Molecure) sign a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02, further solidifying SyVento's reputation in the field
SyVento BioTech opens its state-of-the-art R&D facility, expanding its research capabilities in lipid-based drug delivery systems and RNA-based medicine. This advanced research and production facility distinguishes the company as a standout in this part of the world, reflecting its commitment to innovation and excellence
Xucheng Hou, Tal Zaks, Robert Langer, Yizhou Dong. ” Lipid nanoparticles for mRNA delivery.” Nature Reviews Materials volume 6, (2021): pages1078–1094. https://doi.org/10.1038/s41578-021-00358-0